SAR650984
Total Payments
$735,822
Transactions
331
Doctors
7
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $735,822 | 331 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $726,870 | 323 | 98.8% |
| Consulting Fee | $8,399 | 3 | 1.1% |
| Travel and Lodging | $366.88 | 2 | 0.0% |
| Food and Beverage | $186.00 | 3 | 0.0% |
Payments by Type
Research
$726,870
323 transactions
General
$8,952
8 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patie | SANOFI US SERVICES INC. | $585,116 | 1 |
| A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD3 | SANOFI US SERVICES INC. | $37,096 | 0 |
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) | SANOFI US SERVICES INC. | $17,887 | 0 |
| An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients With Relapsed/Refractory Multiple Myeloma | SANOFI US SERVICES INC. | $11,448 | 0 |
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | SANOFI US SERVICES INC. | $5,764 | 0 |
| IST- Tolerance Combination Dose-Carfilzomide-IV | SANOFI US SERVICES INC. | $4,799 | 0 |
| A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumo | SANOFI US SERVICES INC. | $2,100 | 0 |
| IST-1L-Smoldering myeloma-PT- IV | SANOFI US SERVICES INC. | $553.16 | 0 |
| Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | SANOFI US SERVICES INC. | $533.97 | 0 |
| Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia | SANOFI US SERVICES INC. | $463.67 | 0 |
| Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY) | SANOFI US SERVICES INC. | $431.73 | 0 |
| Anti-CD38 naked mAb - isatuximab | SANOFI US SERVICES INC. | $299.22 | 0 |
Top Doctors Receiving Payments for SAR650984
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $719,617 | 318 |
| , MD | Internal Medicine | Rochester, MN | $7,253 | 5 |
| , MD | Hematology & Oncology | Houston, TX | $5,029 | 2 |
| , MD | Hematology & Oncology | Los Angeles, CA | $2,607 | 1 |
| , MD | Hematology & Oncology | Little Rock, AR | $1,086 | 1 |
| , MD | Hematology & Oncology | Nashville, TN | $105.91 | 2 |
| , M.D | Medical Oncology | Houston, TX | $62.00 | 1 |
| , M.D | Medical Oncology | Hackensack, NJ | $62.00 | 1 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $666,491
- SANOFI-AVENTIS U.S. LLC $69,330
Product Information
- Type Drug
- Total Payments $735,822
- Total Doctors 7
- Transactions 331
About SAR650984
SAR650984 is a drug associated with $735,822 in payments to 7 healthcare providers, recorded across 331 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2017. In 2017, $735,822 was paid across 331 transactions to 7 doctors.
The most common payment nature for SAR650984 is "Unspecified" ($726,870, 98.8% of total).
SAR650984 is associated with 12 research studies, including "A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patie" ($585,116).